LC
HUMA icon

Lindbrook Capital’s Humacyte HUMA Stock Holding History

Lindbrook Capital’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$651 Buy
+382
New +$1.43K ﹤0.01% 2563
2022
Q1 		– Sell
-200
Closed -$1K – 2539
2021
Q4 		$1K Buy
+200
New +$1.98K ﹤0.01% 1934

Other funds holding HUMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 8.03% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Lindbrook Capital's HUMA Position: Q1 2025 in Review

Lindbrook Capital opened a new position in Humacyte (HUMA) in Q1 2025: 382 shares worth $651. The stake represents ﹤0.01% of the portfolio and ranks #2563 among its holdings. This is a return to the name: Lindbrook Capital previously reported a position in HUMA as recently as Q4 2021.

Lindbrook Capital first reported a position in HUMA in Q4 2021 and has held it in 2 quarters since. The position peaked at $1K in Q4 2021. 168 funds tracked by Wall St. Rank hold HUMA as of Q1 2025.

  • Lindbrook Capital held 382 shares of Humacyte worth $651 as of Q1 2025.
  • Humacyte was a new Lindbrook Capital position in Q1 2025.
  • Humacyte made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2563 holding.
  • Lindbrook Capital first reported a position in Humacyte in Q4 2021 and has held it in 2 quarters since.
  • Lindbrook Capital's Humacyte position peaked at $1K in Q4 2021.
  • 168 funds tracked by Wall St. Rank held Humacyte as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.